U.S. Markets closed

Novartis AG (NVS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
84.41+0.27 (+0.32%)
At close: 4:00PM EDT

84.41 0.00 (0.00%)
After hours: 4:16PM EDT

Sign in to post a message.
  • T
    Why NVS is interested in ARCUS technology - Inhale Medicine Technology matters
    ACOR matters
  • T
    My ACOR friends is this a buyout company?
  • M
    Will Novartis buy Ocugen?

    Ocugen is developing gene therapeutics against inherited retinal diseases.

    The portfolio of Ocugen is extremly promising and it must be discussed if Novartis will make a take over of OCGN and its genetherapeutic programm against Age Related Maculadegeneration and inherited retinal diseases like Retinitis pigmentosa.
  • K
    Novartis is rumored to buy REGENXBIO for $90. It developed Zolgensma with them and owes them 500 ,million in milestones, and up to a 13% tiered royalty, that is much more than the tiny 1 billion market cap, RGNX has 100 aav gene library and a $10 B gene therapy for wet AMD
  • K
    Our company is buying RGNX for $90 in Novartis stock and cash. NVS is paying 11% royalties and 500 million in milestones to market cap $1 Billion RGNX. It is cheaper to buy co. than to Pay royalties and milestones to Regenxbio= RGNX. RGNX has 10 Billion RGX 314 drug for wet AMD. It also licenses out it 100 AAV gene library. RGNX is only $29.
  • K
    Rather than buy more NVS, I am buying $29 RGNX and NVS will pay $90 in cash and stock
  • M
    Mr. Buddah
    Nvta warming up, will fly right by, morgan 38 target

    Uxin and nkla only get stronger as day drags on.

  • K
    Koala 🐨 Bear
    Is Novartis going to make a play for Novavax? Does this make since to anyone?
  • S
    If you’re looking for a short and sweet guide to the day’s biggest news, I recommend (http://bestpix.xyz). They breakdown the most important pre-market news and it only takes a few minutes to read.
  • J
    Anybody here? Not a lot of excitement for this company, huh?
  • S
    $ALNY conversation
    The $NVS $ALNY Orion-11 results for Inclisiran have been posted on the CT site. Looks pretty good.

  • c
    Nvs needs to buy a winner in a big way and do something very different. Enter the bidding war that takes place soon for nvta before year end.
  • t
    Looks like Novartis will owe 9 figures in royalties to RGNX for a very long time with approval of Zolgensma.At 1.7 billion market cap of RGNX with its 450 million in cash and 0 debt, it would be much cheaper to buy RGNX as it also owns a 100 AAV gene library which has a private market value of $6 billion USD
  • C
    Biggest winner is the babies. Then biggest winner is RGNX = Regenex bio which gets 9-13 % royalties on Zolgensma which makes it 9 figures on royalties or $6-7 eps in 24 months. AT RGNX $48 it has $450 million in cach and 0 debt and sells at book value. It owns the $6 billion private market value 100 AAV gene platform which is used by every gene therapy drug to make it work as a gene vector. RGNX worth over $155+ a share and is involved in ALS= Lou Gehrigs disease and Rett syndrome and SMA type 1 and Sma type 2 with Novartis.
  • T
    The stock will climb into the 90's next week. I will add on to my position on Tuesday. Very impressive week for NVS. Deep pipeline makes NVS a stock with a lot price appreciation for years to come.
  • T
    Might go down below $10.
  • t
    FDA Accepts AveXis’ BLA for SMA Drug Zolgensma Under Priority Review
    MDA STAFF 12/03/2018
    Today, Novartis, the parent company of AveXis Inc., announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) under Priority Review for Zolgensma (formerly known as AVXS-101), a gene therapy for the treatment of spinal muscular atrophy (SMA) type 1. Priority Review status requires the FDA to review the application and make a decision on whether to approve Zolgensma within six months (the typical review period is 10 months). An anticipated decision is expected in May 2019.

    Zolgensma is a gene therapy that targets the root cause of SMA by delivering a gene to replace the missing or mutated survival of the motor neuron 1 (SMN1) gene. The therapy is a one-time infusion. SMA is a genetic disease affecting the part of the nervous system that controls voluntary muscle movement. Infants with SMA type 1 typically do not survive more than two years.

    Treatment with the therapy in a Phase 1 clinical trial was associated with an increased survival rate compared to the normal course of the disease and the achievement and maintenance of motor milestones that infants with SMA type 1 normally would not be expected to achieve. In the START trial, all 15 patients infused with Zolgensma — three with low dose, 12 with high dose — were alive and event-free at 24 months, compared to 8 percent in a natural history study. An “event” was defined as either death, or at least 16 hours per day of required ventilation support for breathing for 14 consecutive days in the absence of acute reversible illness or surgery. At 24 months, 11 of the 12 high-dose patients could keep their head erect for more than three seconds and sit without support for more than five seconds, 10 patients were able to sit without support for more than 10 seconds, 9 patients were able to sit without support for more than 30 seconds and two patients were able to stand and walk alone without assistance.

    The trial also showed meaningful respiratory results. Of the 10 patients who were not using non-invasive ventilation (NIV) at the start of the trial, seven of them remained NIV-free after 24 months. More importantly, all patients, whether ventilated or not, survived respiratory hospitalizations without tracheostomy or permanent ventilation.

    The most commonly observed side effect of Zolgensma was elevated liver enzymes.

    This announcement underscores the importance of newborn screening to diagnose SMA before babies are symptomatic so they can be treated as early as possible. With the news earlier in the year of SMA being added to the national Recommended Uniform Screening Panel (RUSP), this latest announcement makes it even more important for states to add SMA to their respective newborn screening panels to find babies who may benefit from approved therapies or be eligible to participate in clinical trials.

    Zolgensma is currently in Phase 3 clinical trials for SMA type 1 and is also being tested in a Phase 1 trial for SMA type 2. Additionally, Zolgensma is being tested in a Phase 3 trial for pre-symptomatic newborns diagnosed with SMA types 1, 2 and 3.

    For information regarding eligibility criteria for currently enrolling or planned clinical trials, view the listings on www.ClinicalTrials.gov or www.studysmanow.com, or contact medinfo@avexis.com.

    For more information regarding Zolgensma, check back at mda.org.

    Click here to read the press release from AveXis.
    Home - ClinicalTrials.gov
  • A
    $AMRN , JT presentation today is super strong BP wake up and buyout this company even at $50B looks cheap going forward $PFE $AMGN. $NVS. $GSK spend the money it’s worth it, ADA Standard of Care , Diabetes community is a very lucrative big market 90 million of them according to JT , wow that alone counts in BILLIONS, JT always says we’re not competing in Statins $500B markets but Triglycerides and Cholesterol is entangled now that will take many BILLIONS from that, Atherosclerosis, Alzheimer’s and Cancers future collaborators are looking at that too, AMRN is severely undervalued here and should be close to $100/Shares, A game changer just like $BYND and $UBER in each industry
  • A
    Imagine Pfizer sales force selling Vascepa’s right now the $2B to $4B sales easily achieved (above 500 Triglycerides) some off label use too, Now the sNDA as we know it is 20X bigger (150 to 500) US alone, new report is China’s 185M People have very high Triglycerides, this one is massive going forward, $NVS or $PFE will have epic buyout